Sign in

TCBP on NASDAQ

TC Biopharm

TC Biopharm is a British pharmaceutical company that raised $7.3 million in 2022 (SEC Form D).1 It was founded in 2013 by Angela Scott.1 It is headquartered in Edinburgh.1 Its shares trade on NASDAQ under the symbol TCBP.1

Price unavailable

Last updated Oct 21, 2026.

Overview

-$15.3MNet income, fiscal 20244
2013Founded1

Compare with another stock.

  • TickerTCBP on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersEdinburgh1
  • Websitewww.tcbiopharm.com
  • Legal formprivate company limited by shares1
  • Incorporated inUnited Kingdom5
  • Business addressMaxim 1, 2 Parklands Way, Holytown, X0 Ml1 4Wr5
  • Filer categoryNon-accelerated filer, Emerging growth company5
  • LEI5493006WD64125Z378843
  • StatusActive3
  • LEI statusIssued and current3
  • Registered addressC/O ALVAREZ & MARSAL EUROPE LLP, G2 5NW Glasgow, United Kingdom3
  • Registered withCompanies House, SC7130983

See how the biggest companies compare on our leaderboards

BioPharm (Holdings) Limited and, as a result, TC BioPharm Limited became a wholly owned subsidiary of TC BioPharm (Holdings) Limited.6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in GBP, the currency the company reports in.

Key numbers, fiscal 2022

-314.3%Operating margin4
-36.1%Net margin7
94.3%Revenue growth, 20224
-14.8M GBPFree cash flow7

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development47¢7.6M GBP
  • Interest42¢6.8M GBP
  • Income tax11¢1.7M GBP

Out of 3.8M GBP in revenue.47 The company lost money this year.

Financial statements

Revenue8743.8M GBP in 2022+12% since 2019
01.0M GBP2.0M GBP3.0M GBP4.0M GBP2019: 3.4M GBP3.4M GBP20192020: 2.0M GBP2.0M GBP2020−42%2021: 2.0M GBP2.0M GBP2021+0%2022: 3.8M GBP3.8M GBP2022+94%
Operating income874-12.1M GBP in 2022+20% since 2019
-15.0M GBP-10.0M GBP-5.0M GBP02019: -10.1M GBP-10.1M GBP20192020: -8.3M GBP-8.3M GBP2020−17%2021: -9.3M GBP-9.3M GBP2021+12%2022: -12.1M GBP-12.1M GBP2022+29%
Net income87-1.4M GBP in 2022−77% since 2019
-15.0M GBP-10.0M GBP-5.0M GBP02019: -6.1M GBP-6.1M GBP20192020: -5.5M GBP-5.5M GBP2020−10%2021: -13.6M GBP-13.6M GBP2021+149%2022: -1.4M GBP-1.4M GBP2022−90%
Fiscal year20182019202020212022
Revenue3.4M GBP82.0M GBP72.0M GBP73.8M GBP4
Research and development6.2M GBP77.6M GBP4
Operating expenses15.9M GBP4
Operating income-10.1M GBP8-8.3M GBP7-9.3M GBP7-12.1M GBP4
Interest3.4M GBP76.8M GBP10
Income before tax-15.0M GBP7-3.0M GBP4
Income tax-1.4M GBP7-1.7M GBP4
Net income-6.1M GBP8-5.5M GBP7-13.6M GBP7-1.4M GBP7
Earnings per share-14 GBP/shares7-35 GBP/shares7-2 GBP/shares4
Earnings per share (diluted)-2 GBP/shares4
Shares (weighted, basic)687.2K shares4
Shares (weighted, diluted)687.2K shares4

Compare TC Biopharm with another company

Corporate structure

TC Biopharm sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of TC Biopharm

  • ARMISTICE CAPITAL, LLC Filed SC 13G/A on TC Biopharm, latest Nov 14, 2024 (3 filings since Feb 14, 2023)
  • MEDINET Co., Ltd. Filed SC 13G/A on TC Biopharm, latest Jan 29, 2024 (2 filings since Jan 30, 2023)
  • Nipro Filed SC 13G on TC Biopharm, latest Feb 28, 2023
  • Renaissance Capital Partners Ltd Filed SC 13D/A on TC Biopharm, latest Jan 11, 2023 (2 filings since Apr 27, 2022)
  • Alta Partners LLC Filed SC 13G on TC Biopharm, latest Mar 17, 2022
  • Enterprise Scottish Filed SC 13D on TC Biopharm, latest Feb 22, 2022
  • TC Biopharm Glasgow, United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What TC Biopharm reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation5.5M GBP4 Dec 31, 20245.4M GBP4 Dec 31, 2023+1.2%
Accumulated depreciation4.5M GBP4 Dec 31, 20244.2M GBP4 Dec 31, 2023+9.2%
Property and equipment, net954.8K GBP4 Dec 31, 20241.3M GBP4 Dec 31, 2023−25.1%
Operating-lease assets (leased space)1.1M GBP4 Dec 31, 20241.3M GBP4 Dec 31, 2023−15.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.5M4 Dec 31, 2024

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)466.3K GBP4 Dec 31, 2024615.2K GBP4 Dec 31, 2023−24.2%
Finite-lived intangibles, gross723.9K GBP4 Dec 31, 2024860.6K GBP4 Dec 31, 2023−15.9%
Accumulated amortization384.8K GBP4 Dec 31, 2024245.4K GBP4 Dec 31, 2023+56.8%

The story

Founded by Angela Scott in 2013.1

Leadership

Who has led TC Biopharm, and when. Pick a name to see everywhere that person has worked.

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorMartin Thorp named Dec 13, 202211
  • DirectorArlene Morris named Dec 13, 202211
  • DirectorBryan Kobel named Dec 13, 202211
  • DirectorEdward Niemczyk named Dec 13, 202211
  • DirectorJames Culverwell named Dec 13, 202211
  • DirectorMark Bonyhadi named Dec 13, 202211
  • DirectorMichael Leek named Dec 13, 202211

Former names

  • TC BioPharm (Holdings) LtdJul 26, 2021 to Dec 23, 20215

Timeline

  1. Jun 28, 20248-K Executive or director change12
  2. May 29, 20248-K Listing notice or transfer13
  3. May 20, 20248-K Other events14
  4. May 8, 20248-K Entered a material agreement; Unregistered sale of shares; Other events15
  5. May 6, 20248-K Other events16
  6. Apr 4, 20248-K Other events17
  7. Mar 19, 20248-K Shareholder vote18
  8. Mar 18, 20248-K Unregistered sale of shares19
  9. Mar 12, 20248-K Unregistered sale of shares; Executive or director change20
  10. Mar 6, 20248-K Executive or director change21
  11. Feb 14, 20248-K Regulation FD disclosure; Other events22
  12. Jan 4, 20248-K Listing notice or transfer; Other events23
  13. Feb 2022Went public Listed on NASDAQ1
  14. 2013Founded Founded1

Filings

192 filings to the SEC since October 2021: 5 annual reports, 1 quarterly reports, 12 major events, 10 insider forms, 10 large holders, 1 private raises, 153 other. The latest 20:

  1. Dec 3, 202515-12G EDGAR
  2. Nov 17, 20256-K EDGAR
  3. Oct 7, 20256-K EDGAR
  4. Sep 2, 20256-K EDGAR
  5. Aug 5, 20256-K EDGAR
  6. May 27, 20256-K EDGAR
  7. May 9, 202520-F EDGAR
  8. May 6, 20256-K EDGAR
  9. Apr 30, 2025NT 20-F EDGAR
  10. Mar 21, 20256-K EDGAR
  11. Feb 10, 20256-K EDGAR
  12. Jan 8, 20256-K EDGAR
  13. Jan 8, 20256-K EDGAR
  14. Dec 31, 20246-K EDGAR
  15. Dec 30, 20246-K EDGAR
  16. Dec 17, 20246-K EDGAR
  17. Dec 16, 2024424B5 EDGAR
  18. Dec 16, 20246-K EDGAR
  19. Dec 11, 2024EFFECT EDGAR
  20. Dec 9, 2024CORRESP EDGAR

The 192 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 7 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 30, 2022Randall Diana Elizabeth10% ownerBuy70,000$5.00$350.0KForm 4
Nov 30, 2022Randall Mark Edward10% ownerBuy70,000$5.00$350.0KForm 4
Nov 30, 2022Randall Kenneth Edward10% ownerBuy70,000$5.00$350.0KForm 4
Nov 30, 2022Randall Mark Edward10% ownerBuy70,000$5.00$350.0KForm 4
Nov 30, 2022Randall Kenneth Edward10% ownerBuy70,000$5.00$350.0KForm 4
Nov 30, 2022Renaissance Capital Partners Ltd10% ownerBuy70,000$5.00$350.0KForm 4
May 24, 2022Randall Kenneth Edward10% ownerBuy20,803$1.15$23.9KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$7.3M 2022–2022
Money received by yearMoney received by year, 2022–2022: $7.3M in all. Private raises (Form D) $7.3M.$0$2M$4M$6M$8M2022 · Private raises (Form D): $7.3M2022
Figures by year
YearPrivate raises (Form D)Total
2022$7.3M$7.3M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Nov 30, 2022Raised $7.3 million in a private offering of securities11 Form D: 2 investors so far Form D

SEC filer profile

How TC Biopharm is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTC BioPharm (Holdings) plc2
  • CIK0001872812
  • Filer statusNon-accelerated filer an emerging growth company; a shell company6
  • Incorporated inX06
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business addressMaxim 1, 2 Parklands Way, Holytown, X0 ML1 4WR2
  • Phone014143375572
  • Shares outstanding1,991,478,441 shares as of Dec 31, 20246
  • Public float$3.1M as of Jun 30, 202330
  • AuditorMarcum LLP, New York, USA PCAOB ID 688; no auditor attestation of internal control over financial reporting6
  • On EDGAR sinceJul 26, 20212
  • Filings198 in all: 6-K (48), CORRESP (30), UPLOAD (13), 8-K (12), F-1/A (12), EFFECT (10), 424B4 (7), F-1 (7)2
    All 39 form types

    424B3 (6), 4 (5), SC 13G (4), 20-F (3), 3 (3), DRS (3), SC 13G/A (3), 4/A (2), DEF 14A (2), DRSLTR (2), F-1MEF (2), F-3 (2), NT 20-F (2), PRE 14A (2), SC 13D (2), 10-K (1), 10-K/A (1), 10-Q (1), 15-12G (1), 25-NSE (1), 424B1 (1), 424B5 (1), 8-A12B (1), CERT (1), D (1), DRS/A (1), F-3/A (1), POS EX (1), S-3 (1), S-3/A (1), SC 13D/A (1)

  • Latest filingsAnnual report (20-F) May 9, 2025
    Quarterly report (10-Q) May 15, 2024
    Proxy statement (DEF 14A) Jun 7, 2024
    Latest 8-K (8-K) Jun 28, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
    SEC EDGAROther events
  15. 15
  16. 16
    SEC EDGAROther events
  17. 17
    SEC EDGAROther events
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30